Viridian Therapeutics, Inc. Common Stock
VRDNViridian Therapeutics, Inc. (VRDN) is a biopharmaceutical company focused on developing innovative therapies for patients with rare and severe diseases. The company primarily concentrates on ophthalmic conditions, leveraging its expertise in antibody engineering and targeted biologics to address unmet medical needs.
Company News
4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
Viridian Therapeutics reported Q2 2025 results, highlighting progress in thyroid eye disease treatment with veligrotug, securing FDA Breakthrough Therapy Designation and a $70 million licensing deal with Kissei Pharmaceutical, while experiencing increased research expenses and net losses.
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 26.17% and 10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
